James Dillard Net Worth

The estimated Net Worth of James E Iii Dillard is at least $6.75 Million dollars as of 10 March 2023. Mr. Dillard owns over 9,000 units of Perrigo plc stock worth over $671,725 and over the last 10 years he sold PRGO stock worth over $3,366,826. In addition, he makes $2,714,790 as Executive Vice President and Chief Scientific Officer at Perrigo plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Dillard PRGO stock SEC Form 4 insiders trading

James has made over 13 trades of the Perrigo plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 9,000 units of PRGO stock worth $321,300 on 10 March 2023.

The largest trade he's ever made was selling 26,647 units of Perrigo plc stock on 9 March 2015 worth over $1,434,941. On average, James trades about 3,876 units every 117 days since 2014. As of 10 March 2023 he still owns at least 25,130 units of Perrigo plc stock.

You can see the complete history of Mr. Dillard stock trades at the bottom of the page.

James Dillard biography

James E. Dillard III serves as Executive Vice President, Chief Scientific Officer of the Company. Mr. Dillard joined Perrigo from Altria Group, Inc., where he served as Senior Vice President, Research, Development and Sciences and Chief Innovation Officer from January 2009 to May 2018. During his tenure with Altria Group, Mr. Dillard led the creation of the Regulatory Affairs function in 2009 and also served as Chief Innovation Officer for Altria Client Services and Senior Vice President of Research, Development & Regulatory Affairs for Altria Group. He held science and technology leadership roles with U.S. Smokeless Tobacco Company, an Altria Group Inc. operating company, from 2001 to 2009. Mr. Dillard worked for the U.S. Food and Drug Administration between 1987 and 2001 as Director of the Division of Cardiovascular and Respiratory Devices, as well as in various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.

What is the salary of James Dillard?

As the Executive Vice President and Chief Scientific Officer of Perrigo plc, the total compensation of James Dillard at Perrigo plc is $2,714,790. There are 4 executives at Perrigo plc getting paid more, with Murray Kessler having the highest compensation of $10,807,800.

How old is James Dillard?

James Dillard is 56, he's been the Executive Vice President and Chief Scientific Officer of Perrigo plc since 2019. There are 19 older and 8 younger executives at Perrigo plc. The oldest executive at Perrigo Company plc is Rolf Classon, 75, who is the Independent Director.

What's James Dillard's mailing address?

James's mailing address filed with the SEC is C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN, MI, 49010.

Insiders trading at Perrigo plc

Over the last 11 years, insiders at Perrigo plc have traded over $21,020,805 worth of Perrigo plc stock and bought 592,512 units worth $38,708,035 . The most active insiders traders include Jeffrey C Smith, Gary M Cohen, and Joseph C Papa. On average, Perrigo plc executives and independent directors trade stock every 11 days with the average trade being worth of $156,424. The most recent stock trade was executed by Ronald Craig Janish on 26 August 2024, trading 13,000 units of PRGO stock currently worth $382,200.

What does Perrigo plc do?

perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).

Complete history of Mr. Dillard stock trades at Altria and Perrigo plc

Perrigo plc executives and stock owners

Perrigo plc executives and other stock owners filed with the SEC include:

• Murray Kessler,
  President, Chief Executive Officer, Director
• Raymond Silcock,
  Chief Financial Officer, Executive Vice President
• Murray S. Kessler,
  CEO, Pres & Director
• Todd Kingma,
  Executive Vice President, General Counsel, Company Secretary
• James Dillard,
  Executive Vice President, Chief Scientific Officer
• Svend Andersen,
  Executive Vice President, President - Consumer Healthcare International
• Sharon Kochan,
  Executive Vice President, President - RX Pharmaceuticals
• Raymond P. Silcock,
  CFO, Principal Accounting Officer & Exec. VP
• Svend Andersen,
  Exec. VP & Pres of Consumer Healthcare International
• Richard S. Sorota,
  Exec. VP & Pres of Consumer Self-Care Americas
• Todd W. Kingma,
  Exec. VP, Gen. Counsel & Sec.
• James E. Dillard III,
  Exec. VP & Pres of Consumer Self-Care Americas
• Rolf Classon,
  Independent Director
• Donal O'Connor,
  Independent Director
• Jeffrey Kindler,
  Independent Director
• Theodore Samuels,
  Independent Director
• Geoffrey Parker,
  Independent Director
• Bradley Alford,
  Independent Director
• Adriana Karaboutis,
  Independent Director
• Erica Mann,
  Independent Director
• Bradley Joseph,
  Vice President Global Investor Relations
• Katherine Doyle,
  Director
• Rich Sorota,
  Executive Vice President and President - Consumer Self-Care Americas
• Grainne Quinn,
  Executive Vice President, Chief Medical Officer
• Ronald Janish,
  Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer
• Thomas Farrington,
  Executive Vice President, Chief Information Officer
• Robert Willis,
  Chief Human Resource Officer, Executive Vice President
• Kyle L. Hanson,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Alison Ives,
  Exec. VP & Chief Scientific Officer
• Eduardo Guarita Bezerra,
  Exec. VP & CFO
• Mary Reilly-Brest,
  Director of Global Organizational and Human Resource Devel.
• Thomas M. Farrington,
  Chief Information Officer & Exec. VP
• Shannon Hukill,
  Sr. Director of Technical Operations
• Ronald C. Janish,
  Chief Transformation Officer and Exec. VP of Global Operations & Supply Chain
• Patrick Lockwood Taylor,
  CEO
• Paul Weninger,
  EVP, Quality Operations
• James R Michaud,
  EVP, Chief HR Officer
• John T Hendrickson,
  EVP Global Operations & Supply
• Gary M Cohen,
  Director
• John Wesolowski,
  EVP, President Rx
• Michael J Jandernoa,
  Director
• Judy L Brown,
  Executive VP & CFO
• Laurie Brlas,
  Director
• Jeffrey C Smith,
  Director
• Triona Schmelter,
  EVP & President CSCA
• Uwe Roehrhoff,
  CEO
• Ronald Winowiecki,
  CFO
• David Ball,
  EVP & CBDO
• Jacqualyn A Fouse,
  Director
• Ellen Randi Hoffing,
  Director
• Louis Yu,
  Executive VP Global Quality
• Shlomo Yanai,
  Director
• Marc Coucke,
  Executive VP & GM
• Michael Robert Stewart,
  Sr. VP Global Human Resources
• Joseph C Papa,
  President and CEO
• Gary K Jr Kunkle,
  Director
• Herman Jr Morris,
  Director
• Ben Zion Zilberfarb,
  Director
• Ran Gottfried,
  Director
• Jatin Shah,
  Sr VP & Chief Scientific Offic
• Scott F Jamison,
  
• David T Gibbons,
  Director
• Douglas Boothe,
  EVP & GM Perrigo Pharma
• Jeffrey Needham,
  EVP, President CHC Americas
• Orlando D Ashford,
  Director
• Alison Ives,
  EVP & Chief Scientific Officer
• Kyle Hanson,
  EVP & General Counsel
• Eduardo Guarita Bezerra,
  EVP & Chief Financial Officer
• Albert Manzone,
  Director
• Julia M Brown,
  Director